GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production

Arthritis and Rheumatism

Volumn 63, Issue 6, 2011, Pages 1738-1747

  Medsger Jr , Thomas A ^a   Ivanco, Dana E ^a   Kardava, Lela ^a   Morel, Penelope A ^b   Lucas, Mary R ^b   Fuschiotti, Patrizia ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 13; SMALL INTERFERING RNA; STAT6 PROTEIN; TRANSCRIPTION FACTOR GATA 3;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INTERSTITIAL LUNG DISEASE; LYMPHOCYTE CULTURE; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC SCLEROSIS; UPREGULATION; BIOSYNTHESIS; DIFFUSE SCLERODERMA; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; DOWN-REGULATION; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-13; MALE; MIDDLE AGED; RNA, SMALL INTERFERING; SCLERODERMA, DIFFUSE; UP-REGULATION;

EID: 80051816813     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30489     Document Type: Article

References (50)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003;29: 255-73, vi. (Pubitemid 36765120)
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
4. Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008;38:132-60.
5. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67. (Pubitemid 46348510)
6. Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977;20:975-84.
7. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
8. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53. (Pubitemid 14089474)
9. Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999;42:1168-78. (Pubitemid 29268953)
10. Chizzolini C. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events. Ann Med 2007; 39:42-53. (Pubitemid 46277058)
11. Whiteside TL, Buckingham RB, Prince RK, Rodnan GP. Products of activated mononuclear cells modulate accumulation of collagen by normal dermal and scleroderma fibroblasts in culture. J Lab Clin Med 1984;104:355-69. (Pubitemid 14026534)
12. Fuschiotti P, Medsger TA Jr, Morel PA. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 2009;60:1119-28.
13. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999;190:815-26.
14. Kahaleh MB, Fan PS. Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 1997;83: 32-40.
15. Wynn TA. Fibrotic disease and the TH1/TH2 paradigm. Nat Rev Immunol 2004;4:583-94.
16. Wills-Karp M, Finkelman FD. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal 2008;1: pe55.
17. Andrew DP, Chang MS, McNinch J, Wathen ST, Rihanek M, Tseng J, et al. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by mono-cytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol 1998;161:5027-38. (Pubitemid 28492085)
18. Aliprantis AO, Wang J, Fathman JW, Lemaire R, Dorfman DM, Lafyatis R, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A 2007;104:2827-30. (Pubitemid 46327964)
19. Granel B, Chevillard C, Allanore Y, Arnaud V, Cabantous S, Marquet S, et al. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics 2006;58:693-9. (Pubitemid 44100416)
20. Granel B, Allanore Y, Chevillard C, Arnaud V, Marquet S, Weiller PJ, et al. IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol 2006;33:2015-9. (Pubitemid 44571875)
21. Agarwal S, Rao A. Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity 1998;9:765-75. (Pubitemid 29024456)
22. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996;4:313-9. (Pubitemid 26132509)
23. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997;89:587-96. (Pubitemid 27511769)
24. Ansel KM, Djuretic I, Tanasa B, Rao A. Regulation of Th2 differentiation and I14 locus accessibility. Annu Rev Immunol 2006;24:607-56.
25. Lavenu-Bombled C, Trainor CD, Makeh I, Romeo PH, Max-Audit I. Interleukin-13 gene expression is regulated by GATA-3 in T cells: role of a critical association of a GATA and two GATG motifs. J Biol Chem 2002;277:18313-21. (Pubitemid 34952375)
26. Zhou M, Ouyang W. The function role of GATA-3 in Th1 and Th2 differentiation. Immunol Res 2003;28:25-37. (Pubitemid 37088540)
27. Kishikawa H, Sun J, Choi A, Miaw SC, Ho IC. The cell type-specific expression of the murine IL-13 gene is regulated by GATA-3. J Immunol 2001;167:4414-20. (Pubitemid 32954318)
28. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
29. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6. (Pubitemid 32660630)
30. Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007;56:2740-6. (Pubitemid 47237293)
31. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
32. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42. (Pubitemid 41111469)
33. Ho IC, Glimcher LH. Transcription: tantalizing times for T cells. Cell 2002;109 Suppl: S109-20. (Pubitemid 34457856)
34. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleu-kin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
35. Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003;14:537-50. (Pubitemid 37296026)
36. + T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15:297-322. (Pubitemid 27169283)
37. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998;8:275-83. (Pubitemid 28188888)
38. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-7 production in CD4 and CD8 T cells. Science 2002;295:338-42. (Pubitemid 34074366)
39. Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/Th2 polarization. Immunol Today 2000;21:479-83.
40. Gourh P, Agarwal SK, Divecha D, Assassi S, Paz G, Arora-Singh RK, et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009;60: 3794-806.
41. + T cells. Nat Immunol 2009;10:706-12.
42. Ouyang W, Lohning M, Gao Z, Assenmacher M, Ranganath S, Radbruch A, et al. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 2000;12:27-37. (Pubitemid 30069212)
43. Finkelman FD. Basophils as TH2-inducing APCs: the dog can sing but is it a diva? Immunol Cell Biol 2009;87:568-70.
44. Rankin AL, Mumm JB, Murphy E, Turner S, Yu N, McClanahan TK, et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 2010;184:1526-35.
45. Boin F, De Fanis U, Bartlett SJ, Wigley FM, Rosen A, Casolaro V. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum 2008;58:1165-74. (Pubitemid 351564020)
46. + T cells mediate inflammation and airway hyper-responsiveness. Nat Med 2004;10:865-9. (Pubitemid 39070861)
47. Ray A, Cohn L. Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. J Clin Invest 1999;104: 985-93. (Pubitemid 29536304)
48. Nakamura Y, Ghaffar O, Olivenstein R, Taha RA, Soussi-Gounni A, Zhang DH, et al. Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J Allergy Clin Immunol 1999;103:215-22. (Pubitemid 29095824)
49. Lee GR, Flavell RA Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int Immunol 2004;16:1155-60. (Pubitemid 39136732)
50. Cousins DJ, McDonald J, Lee TH. Therapeutic approaches for control of transcription factors in allergic disease. J Allergy Clin Immunol 2008;121:803-9. (Pubitemid 351458499)